TR200402194T2 - Regulation of excitable tissue function via peripherally administered erythropoietin - Google Patents

Regulation of excitable tissue function via peripherally administered erythropoietin

Info

Publication number
TR200402194T2
TR200402194T2 TR2004/02194T TR200402194T TR200402194T2 TR 200402194 T2 TR200402194 T2 TR 200402194T2 TR 2004/02194 T TR2004/02194 T TR 2004/02194T TR 200402194 T TR200402194 T TR 200402194T TR 200402194 T2 TR200402194 T2 TR 200402194T2
Authority
TR
Turkey
Prior art keywords
erythropoietin
excitable
tissues
tissue function
excitable tissue
Prior art date
Application number
TR2004/02194T
Other languages
Turkish (tr)
Inventor
Brines Michael
Cerami Anthony
Cerami Carla
Original Assignee
The Kenneth S. Warren Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kenneth S. Warren Institute, Inc. filed Critical The Kenneth S. Warren Institute, Inc.
Publication of TR200402194T2 publication Critical patent/TR200402194T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Memelilerde uyarilabilir doku islevini düzenlemek üzere eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisinin sistemik olarak uygulanmasi yoluyla uyarilabilir doku islevini korumak veya gelistirmek için yöntemler ve bilesimler temin edilmistir. Uyarilabilir dokular, beyin gibi merkezi nöronal dokular, periferik nöronal dokular, retina ve kalp dokusudur. Uyarilabilir dokularin korunmasi, hipoksiya, felç bozukluklari, nörodejeneratif hastaliklar, hipoglisemi ve nörotoksin zehirlenmelerinin tedavisini temin eder. Islevin gelistirilmesi, ögrenme bellek için kullanislidir. Bulus moleküllerin kan-beyin engeli gibi siki endoteliyal hücre birlesim yerleri engellerinden naklini kolaylastirmak için bilesimler ve yöntemlere de iliskindir; bu nakil molekülün eritropoietin gibi bir eritropoietin reseptörü etkinligi düzenleyicisi ile birlestirilmesi yoluyla gerçeklestirilir.Methods and compositions are provided for maintaining or improving excitable tissue function by systemically administering an erythropoietin receptor activity regulator such as erythropoietin to regulate excitable tissue function in mammals. Excitable tissues are central neuronal tissues such as the brain, peripheral neuronal tissues, retina and heart tissue. The protection of excitable tissues provides treatment for hypoxia, stroke disorders, neurodegenerative diseases, hypoglycemia and neurotoxin intoxications. The function development is useful for learning memory. The invention also relates to compounds and methods for facilitating the transport of molecules of the invention through tight endothelial cell junction barriers such as blood-brain barrier; this transport is carried out by combining the molecule with an erythropoietin receptor activity regulator such as erythropoietin.

TR2004/02194T 1999-04-13 2000-04-13 Regulation of excitable tissue function via peripherally administered erythropoietin TR200402194T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (1)

Publication Number Publication Date
TR200402194T2 true TR200402194T2 (en) 2004-10-21

Family

ID=26966493

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03785T TR200103785T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via erythropoietin administered peripherally
TR2004/02194T TR200402194T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via peripherally administered erythropoietin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/03785T TR200103785T2 (en) 1999-04-13 2000-04-13 Regulation of excitable tissue function via erythropoietin administered peripherally

Country Status (21)

Country Link
EP (1) EP1171147A4 (en)
JP (1) JP2003520194A (en)
KR (2) KR100883232B1 (en)
CN (1) CN1607957B (en)
AU (1) AU784550B2 (en)
BG (1) BG65353B1 (en)
BR (1) BR0009737A (en)
CA (1) CA2383940A1 (en)
CR (1) CR6501A (en)
CZ (1) CZ20013695A3 (en)
EA (1) EA004766B1 (en)
HU (1) HUP0201598A3 (en)
IL (2) IL145895A0 (en)
IS (1) IS6104A (en)
MX (1) MXPA01010177A (en)
NO (1) NO20014991L (en)
NZ (4) NZ545478A (en)
PL (1) PL352223A1 (en)
SK (1) SK14412001A3 (en)
TR (2) TR200103785T2 (en)
WO (1) WO2000061164A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003089468A1 (en) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
AU2001267882A1 (en) 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for diseases in association with demyelination
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
EP1471871B1 (en) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ATE542904T1 (en) 2001-10-29 2012-02-15 Crucell Holland Bv METHOD AND MEANS FOR PRODUCING PROTEINS WITH PREDEFINED POST-TRANSLATIONAL MODIFICATIONS
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004063927A1 (en) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
CA2618396C (en) * 2005-08-05 2018-02-27 Warren Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
JP5542064B2 (en) 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド Tissue protective peptides and peptide analogs to prevent and treat diseases and disorders associated with tissue damage
RU2519695C2 (en) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (en) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia

Also Published As

Publication number Publication date
BG65353B1 (en) 2008-03-31
NZ514690A (en) 2004-07-30
KR101012932B1 (en) 2011-02-08
KR20070094997A (en) 2007-09-27
NZ533098A (en) 2006-04-28
HUP0201598A2 (en) 2002-09-28
NO20014991L (en) 2001-11-15
TR200103785T2 (en) 2002-06-21
WO2000061164A1 (en) 2000-10-19
BG106058A (en) 2002-12-29
KR100883232B1 (en) 2009-02-10
CZ20013695A3 (en) 2002-02-13
EA004766B1 (en) 2004-08-26
CA2383940A1 (en) 2000-10-19
EP1171147A1 (en) 2002-01-16
IL145895A (en) 2010-05-31
HUP0201598A3 (en) 2002-10-28
JP2003520194A (en) 2003-07-02
SK14412001A3 (en) 2002-03-05
MXPA01010177A (en) 2004-09-10
AU4348700A (en) 2000-11-14
NZ560696A (en) 2010-03-26
CN1607957A (en) 2005-04-20
EP1171147A4 (en) 2003-05-14
NZ545478A (en) 2008-04-30
IS6104A (en) 2001-10-11
PL352223A1 (en) 2003-08-11
KR20020000874A (en) 2002-01-05
BR0009737A (en) 2003-01-14
AU784550B2 (en) 2006-05-04
NO20014991D0 (en) 2001-10-12
IL145895A0 (en) 2002-07-25
CR6501A (en) 2004-04-15
CN1607957B (en) 2012-10-10
EA200101073A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
TR200402194T2 (en) Regulation of excitable tissue function via peripherally administered erythropoietin
CY1121447T1 (en) COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY
BRPI0417260A (en) azepinoindole derivatives as pharmaceutical agents
DE60228857D1 (en) AMINO PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PREPARATION AND PHARMACEUTICAL COMPOSITION
BR9714677A (en) "3-pyridyl enantiomers and their use as analgesics"
DE69535805D1 (en) New carbamate and urea derivatives as anti-multidrug resistance agents
TR200103469T2 (en) Prevention and treatment of amyloidogenic disease
DE69130859T2 (en) THERAPEUTIC USES OF MELANINE
ATE314067T1 (en) CANNABINOL-11 ACID DERIVATIVES AS ANTI-INFLAMMATORY AND ANALGESICS
NZ212368A (en) Amide-containing compositions for transdermal and transmembrane penetration of topical and systemic agents
ATE280758T1 (en) AGENTS FOR PROTECTING NERVE CELLS
Man et al. Role of nitric oxide in regulating epidermal permeability barrier function
BR0013065A (en) Method and compound to treat a disease associated with aberrant leukocyte recruitment and / or activation
BR9805734A (en) Derivatives of imidazolin-4-one useful as anticancer agents.
US10682333B2 (en) Composition for inhibiting formation of SNARE complex, containing myricetin derivatives
WO2018081779A1 (en) Skin enhancing compositions and methods
AR029025A1 (en) DERIVATIVES OF ADENOSINA N6 HETEROCICLIC 5 'MODIFIED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
ATE308545T1 (en) CHLOROPHYLL AND BACTERIOCHLOROPHYL ESTERS, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2003137783A (en) Composition and method for using pyridinium derivative for cosmetic and therapeutic application
Powers et al. Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro
EP1060734B1 (en) Use of cyclic enamines as sun protection agents
Namjoshi et al. Cyclic peptides as potential therapeutic agents for skin disorders
Veiga et al. Anti-aging peptides for advanced skincare: focus on nanodelivery systems
KR101453220B1 (en) Compositions for conditioning
JP2004323525A (en) Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent